Hyperthermic intraperitoneal chemotherapy in colorectal cancer

作者：Oliver M. Fisher, Chris Brown, Jesús Esquivel, Stein Gunnar Larsen, Winston Liauw, Nayef Alzahrani, David L. Morris, Vahan Képénékian, Isabelle Sourrouille, Frédéric Dumont, Jean‐Jacques Tuech, Cécilia Ceribelli, Béranger Doussot, Olivia Sgarbură, Mohammed Al-Hosni, François Quénet, Olivier Gléhen, Peter Cashin, Peritoneal Surface Oncology Group International (PSOGI), Nordic Peritoneal Oncology Group (NPOG), American Society for Peritoneal Surface Malignancy (ASPSM) and BIG-RENAPE Groups, Kjersti Flatmark, Wilhelm Graf, Heikki Takala, Andrew M. Lowy, Terence C. Chua, Joerg Pelz, Dario Baratti, Joel Baumgartner, Richard Berri, Pedro Bretcha-Boix, Marcello Deraco, Guillermo Flores-Ayala, Alberto Gómez-Portilla, Santiago González‐Moreno, Martin Goodman, Evgenia Halkia, Shigeki Kusamura, Mecker G. Möller, Guillaume Passot, Marc Pocard, George I. Salti, Armando Sardi, Maheswari Senthil, John Spilioitis, Juan Torres-Melero, Kiran K. Turaga, Jean-Marc Béréder, Jean‐Louis Bernard, Naoual Bakrin, Sébastien Carrère, J Coget, Eddy Cotte, Olivier Facy, Maximiliano Gelli, François-Noël Gilly, Pablo Ortega‐Deballon, Guillaume Passot, Patrick Rat, Pascal Rousset, Emilie Thibaudeau, Delphine Vaudoyer · 发表于：BJS Open · 年份：2024 · DOI：10.1093/bjsopen/zrae017 · 被引用次数：17 · 研究领域：Intraperitoneal and Appendiceal Malignancies、Nanoplatforms for cancer theranostics、Occupational and environmental lung diseases

BACKGROUND: This study evaluated the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer with peritoneal metastases (pmCRC) in a large international data set of patients. PATIENTS AND METHODS: Patients with pmCRC from 39 centres who underwent cytoreductive surgery with HIPEC between 1991 and 2018 were selected and compared for the HIPEC protocols received-oxaliplatin-HIPEC versus mitomycin-HIPEC. Following analysis of crude data, propensity-score matching (PSM) and Cox-proportional hazard modelling were performed. Outcomes of interest were overall survival (OS), recurrence-free survival (RFS) and the HIPEC dose-response effects (high versus low dose, dose intensification and double drug protocols) on OS, RFS and 90-day morbidity. Furthermore, the impact of the treatment time period was assessed. RESULTS: Of 2760 patients, 2093 patients were included. Median OS was 43 months (95% c.i. 41 to 46 months) with a median RFS of 12 months (95% c.i. 12 to 13 months). The oxaliplatin-HIPEC group had an OS of 47 months (95% c.i. 42 to 53 months) versus 39 months (95% c.i. 36 to 43 months) in the mitomycin-HIPEC group (P = 0.002), aHR 0.77, 95% c.i. 0.67 to 0.90, P < 0.001. The OS benefit persisted after PSM of the oxaliplatin-HIPEC group and mitomycin-HIPEC group (48 months (95% c.i. 42 to 59 months) versus 40 months (95% c.i. 37 to 44 months)), P < 0.001, aHR 0.78 (95% c.i. 0.65 to 0.94), P = 0.009. Similarly, matched RFS was significantly higher for oxal...